Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.
about
Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disordersNeurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adultsNeurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adultsCannabinoids As Potential Treatment for Chemotherapy-Induced Nausea and VomitingFosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectivesManagement of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetronPatient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice GuideNausea: a review of pathophysiology and therapeuticsHypnosis for the Management of Anticipatory Nausea and VomitingTreatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical updateProphylactic Management of Radiation-Induced Nausea and VomitingPalonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapyA Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and VomitingTreatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and VomitingPrevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid TumorsPatient-centered management of chemotherapy-induced nausea and vomitingSystemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and managementSerotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting: therapeutically equivalent or meaningfully different?Evolving treatment paradigms for chemotherapy-induced nausea and vomitingSunitinib in the treatment of metastatic renal cell carcinomaNeurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysisRecent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive reviewDifference in the emetic control among highly emetogenic chemotherapy regimens: Implementation for appropriate use of aprepitantGlucocorticoid prescriptions and breast cancer recurrence: a Danish nationwide prospective cohort studyOndansetron and promethazine have differential effects on hypothermic responses to lithium chloride administration and to provocative motion in ratsImpact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey.Palonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two Phase III trials.Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study.Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study.Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patientsOutcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis.The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy-Induced Nausea and Vomiting: Systematic Review of the Literature.A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.Comparison of Antiemetic Effectiveness of Palonosetron Versus Ondansetron in Patients on Cancer Chemotherapy: A Prospective Observational Study in South IndiansCheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting.Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomitingThe effects of intravenous fosaprepitant and ondansetron for the prevention of postoperative nausea and vomiting in neurosurgery patients: a prospective, randomized, double-blinded study.Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trialAntiemetics: American Society of Clinical Oncology clinical practice guideline update.
P2860
Q22299116-3C17DC5E-68D3-4A50-9801-D8771BB2CDE3Q24200792-47FBFE37-6DF9-446E-BC0C-5AD2E66552D1Q26472106-EC57FABE-B173-4344-AFA0-A3A6F7B58CFDQ26738288-E23BCA30-4B03-4712-97E7-CD294A109CE5Q26744323-E83A0804-0F55-4713-8A5B-DCA7EC1F1B99Q26746211-FEA9CEF2-88BE-4C6A-ADA8-F3A1B69A6215Q26749476-E59D59F2-133D-4372-8EE5-2AA425A5120FQ26771877-DEFF4526-527E-4BB4-905E-EC047FE5DC8BQ26777888-CB4732DE-5008-4334-B791-BA23B457B55CQ26778004-168EB3FD-DD5B-4D8C-B7D5-C7A63B0C4F72Q26783184-E21EC70F-1498-4C9A-8BC6-AE0CC448C060Q26783229-3597CF6F-E63E-4C88-B670-287E953471E0Q26784064-3636D245-4623-483B-869B-2CE168D3A184Q26784070-0A7CB407-6254-44F2-8868-83537A462C6CQ26784083-5AE61323-1076-4068-9EB1-CF7AE4378460Q26828354-78F29B47-7756-43F2-A5E8-5A9AEAD2BE9BQ26830695-DCB11B30-54F6-4C67-968C-D289EABF17F1Q27000620-74226B4B-FEC3-498E-A756-17AE8355F052Q27024463-DE788A55-CA2A-44B6-B4DB-0314ADEAEDF0Q28072057-8C7078E5-D145-4FCF-923C-F5FD7529E43DQ28078513-63DACD29-EE0B-4EDE-9428-AC7C0D7EE3EEQ28081186-D6277942-893C-4355-8D5A-FEFCDED2DC22Q28236344-964FCC5F-2D04-4787-9D85-AC392ED288EAQ28397959-2DD9AA73-3EF7-4A19-9E92-50A8F2EBD8EAQ28834289-2C463D4C-19FA-4ADA-A7D6-7708F0CB8E09Q30316569-CAE9AB1B-C4BB-43B2-A29E-82C56B732367Q30672833-14490A01-7DD4-41D8-92FC-C165FD8636C8Q30973575-162290B5-33B4-47E9-97BF-D9A6E9C51BCFQ31045439-BB33965C-4C5C-4255-B439-6335010BE459Q33556570-BD67DF5E-B1DA-4B2E-B33E-05425E75E0C2Q33652946-5281508E-B89B-4F01-B24D-84856D4F2DBDQ33805465-8D80D7B7-5BFE-4366-B3D6-AD383127335FQ33809590-20035BD8-A0B8-407B-B933-67150551EF94Q33832042-66706ED1-129F-48AE-AC82-D47EE6EFA492Q33866119-68EA3CD7-2956-499C-A68B-9A89F7E29B90Q33886138-072AED27-D54A-448A-8FD6-7B10BFA8A907Q33891321-E35F2515-50DA-410B-B878-768FA50B5747Q33992722-65E7B7E4-0BDA-4536-9B2B-D2BE3ABA50C3Q34011870-288F2AC1-39F0-4B33-B9F5-2985B6502B9BQ34030613-9CBF7879-CA90-4203-AE89-74FCB37C1FA9
P2860
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Guideline update for MASCC and ...... Perugia consensus conference.
@ast
Guideline update for MASCC and ...... Perugia consensus conference.
@en
Guideline update for MASCC and ...... Perugia consensus conference.
@nl
type
label
Guideline update for MASCC and ...... Perugia consensus conference.
@ast
Guideline update for MASCC and ...... Perugia consensus conference.
@en
Guideline update for MASCC and ...... Perugia consensus conference.
@nl
prefLabel
Guideline update for MASCC and ...... Perugia consensus conference.
@ast
Guideline update for MASCC and ...... Perugia consensus conference.
@en
Guideline update for MASCC and ...... Perugia consensus conference.
@nl
P2093
P2860
P356
P1433
P1476
Guideline update for MASCC and ...... Perugia consensus conference.
@en
P2093
B L Rapoport
B T Espersen
C Rittenberg
E Ballatori
E Maranzano
ESMO/MASCC Guidelines Working Group
P2860
P304
P356
10.1093/ANNONC/MDQ194
P478
21 Suppl 5
P577
2010-05-01T00:00:00Z